The Inflation Reduction Act and Patient Costs for Drugs to Treat Heart Failure

Figures

• 

  Figure.. Monthly Count of Claims for Dapagliflozin, Empagliflozin, and Sacubitril/Valsartan by Benefit Phase (2021) Claims that straddle multiple benefit phases are included in the benefit phase in which they end. For example, if a claim straddles initial coverage limit (ICL) and catastrophic phases, it is counted as a catastrophic claim. Each bar represents the number of claims for the 3 study drugs falling in that month, stratified by benefit phase. The number of claims varied by month (January, 204 921; February, 181 025; March, 217 491; April, 217 187; May, 215 275; June, 234 838; July, 237 818; August, 245 462; September, 245 390; October, 253 469; November, 259 041; December, 266 867).